Slojab
25 minutes ago
In the case of TWOH, it was for this reason.
TORONTO, April 24, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Two Hands Corporation (OTCQB: TWOH), is pleased to announce that it is considering a dual listing of its common shares on the Canadian Securities Exchange (CSE). The board of directors is meeting with several law firms to review the dual listing requirements.
CEO of Two Hands, Nadav Elituv commented, βThe Canadian Securities Exchange has seen significant increases in trading, particularly in the cannabis and CBD space. We feel that by listing on the exchange we will attract more investors in both the U.S. and Canada, creating further liquidity and increasing our ability to raise capital in a different market. With our operations conducted in Canada and Colombia and our management team residing in Canada, considering a listing on the CSE makes the most sense. We intend to file an application with the CSE in the next few months. A listing could happen as early as the third quarter of the Companyβs current fiscal year and would require certain regulatory approvals that would allow us to market and sell our common shares to Canadian investors.β
dinogreeves
19 hours ago
If there is any merits to this story, they are most probably going to buy more shares out side of the market to have more control, 57% is enough to have do a merger , but not enough to have control, yes, in theory 57% gives them control, but if they are bringing something tangible to the table, they will need another at least 35%, which likely will happen out of the market if they agree on the terms with whoever is holding a substantial control block. Never seen a merger with less than 83% control.
m0n
1 day ago
CFO of NUKK & CERO is on board along with another board member from israelventurepartners.com which is the Silicon Valley of Israel per the 8k filed on 1/10/25
https://www.sec.gov/edgar/browse/?CIK=0001494413
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers; Compensatory Arrangements of Certain Officers. On January 3, 2025, the Board of Directors appointed Andrew Kucharchuk and Craig Marshak as members of the Board of Directors effective immediately. The Board now consists of Emil Assentato, Andrew Kucharchuk and Craig Marshak.The following biographical information is provided:Andrew Kucharchuk, Member of the Board of DirectorsMr. Kucharchuk has been a director of Adhera Therapeutics Inc. since July 7, 2022, and currently serves as its Chief Operating Officer, a position he has held since September 30, 2022. Previously, he was Chief Executive Officer of Adhera Therapeutics from July 7, 2020, to September 30, 2022.Mr. Kucharchuk has been a member of the Board of Directors of Theralink Technologies, Inc. (βTheralinkβ) since 2020, having previously served in this role from September 2015 to March 2017. His executive experience at Theralink includes roles as President and Chief Financial Officer from February 2016 to June 2020, Chief Executive Officer from November 2019 to June 2020, and Acting Chief Financial Officer from June 2020 to September 2020.Craig Marshak, Member of the Board of Directors Mr. Marshak has been a Managing Director at Clear Think Capital since joining the firm in March 2021. From 2018 to 2021, he served as Senior Advisor to SHR Ventures LLC, the family office of Stanley Hutton Rumbough, whose grandfather founded E.F. Hutton. During this time, he co-founded Moringa Acquisition, a NASDAQ-listed SPAC, where he serves as Vice Chairman and Co-Founder.Since 2002, Mr. Marshak has been a Principal at Israel Venture Partners (israelventurepartners.com), a platform focused on identifying and investing in Israeli technology and healthcare companies.
m0n
2 days ago
Well maybe post new SEC Docs not old ones as there has been a CoC (this is an acronym for Change of Control). These new SEC docs hit on Jan 10th in the year 2025.
Next up is the CSE side of things. You don't file with the CSE first stating new board members when you re a USA Based company LoL. You do the USA side of things first, wait until it's posted (in this case the SEC), the. file with the CSE.
Tick Tok MOFO. We have a Baby NUKK here with all those BC SOAC M&A specialists on board
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers; Compensatory Arrangements of Certain Officers. On January 3, 2025, the Board of Directors appointed Andrew Kucharchuk and Craig Marshak as members of the Board of Directors effective immediately. The Board now consists of Emil Assentato, Andrew Kucharchuk and Craig Marshak.The following biographical information is provided:Andrew Kucharchuk, Member of the Board of DirectorsMr. Kucharchuk has been a director of Adhera Therapeutics Inc. since July 7, 2022, and currently serves as its Chief Operating Officer, a position he has held since September 30, 2022. Previously, he was Chief Executive Officer of Adhera Therapeutics from July 7, 2020, to September 30, 2022.Mr. Kucharchuk has been a member of the Board of Directors of Theralink Technologies, Inc. (βTheralinkβ) since 2020, having previously served in this role from September 2015 to March 2017. His executive experience at Theralink includes roles as President and Chief Financial Officer from February 2016 to June 2020, Chief Executive Officer from November 2019 to June 2020, and Acting Chief Financial Officer from June 2020 to September 2020.Craig Marshak, Member of the Board of Directors Mr. Marshak has been a Managing Director at Clear Think Capital since joining the firm in March 2021. From 2018 to 2021, he served as Senior Advisor to SHR Ventures LLC, the family office of Stanley Hutton Rumbough, whose grandfather founded E.F. Hutton. During this time, he co-founded Moringa Acquisition, a NASDAQ-listed SPAC, where he serves as Vice Chairman and Co-Founder.Since 2002, Mr. Marshak has been a Principal at Israel Venture Partners (israelventurepartners.com), a platform focused on identifying and investing in Israeli technology and healthcare companies.Mr. Marshak began his investment banking career at Morgan Stanley in the Merchant Banking department before moving to Corporate Finance and Mergers & Acquisitions at Wertheim Schroder and later Schroders in London, England. He went on to establish the London office of Robertson Stephens and, from 1998 to 2001, was Co-Head of the Nomura Technology Merchant Banking Group in London, specializing in high-growth companies in the Israeli and Silicon Valley sectors.His expertise includes advising on multi-billion-dollar restructuring assignments, such as the privatization of Israel Chemicals from Israeli government ownership, the restructuring of Koor Industries (formerly one of Israelβs largest conglomerates), and the landmark restructuring of Manville Corporation. Mr. Marshak and his team at Schroders led the entirety of the Manville engagement, which was one of the most complex restructurings of its era.Mr. Marshak graduated summa cum laude and Phi Beta Kappa with an A.B. degree from Duke University. He was awarded the Roger Alan Opel Scholarship to the London School of Economics and later earned a J.D. from Harvard Law School.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001494413/000126246325000011/twoh8k1225.htm